arrow
L

Lotta Hansson

Karolinska University Hospital
H指数:35
被引数:3,467

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma.

AVD 是老年经典霍奇金淋巴瘤患者一线治疗中一种有效的化疗基础方案。

2026-04-030
OAAI
Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era

COVID-19大流行在慢性淋巴细胞白血病中的结局:聚焦于极早期阶段和Omicron时代

2025-02-250
OA
Severity of COVID-19 in Individuals with Chronic Lymphocytic Leukemia throughout the Pandemic in Sweden: A Nationwide Multiple Register Cohort Study Conducted from 2020 to 2023

瑞典全国多登记队列研究(2020年至2023年实施):慢性淋巴细胞白血病患者在整个疫情期间的COVID-19严重程度

BLOOD
IF23.1
2024-11-050
PRE
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID
2024-11-010
PRE
Risk of COVID-19 hospitalisation by HIV-status and SARS-CoV-2 vaccination status during pre- and post-Omicron era in a national register-based cohort study in Sweden
2024-09-250
OA
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
2023-12-2211
OA
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia
2023-08-311
OAAI
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID

SARS-CoV-2 mRNA疫苗接种后免疫功能低下个体免疫原性的真实世界评估: 前瞻性临床试验COVAXID的一年随访

2023-08-016
OAAI
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
2023-07-1215
OAAI
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
IMMUNITY
IF26.3
2022-09-0144
OAAI
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
2022-02-0825
OAAI
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
MED
IF11.8
2022-02-0122
OAAI
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
2021-12-01172
OAAI
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients
LEUKEMIA
IF13.4
2021-09-2524
OAAI
Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study
2020-01-2353
OAAI
FFirst-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
2018-11-2236
OAAI